FIT Hon Teng Limited 鴻騰六零八八精密科技股份有限公司 （於開曼群島以鴻騰精密科技股份有限公司的名稱註冊成立的有限公司， 並以鴻騰六零八八精密科技股份有限公司於香港經營業務） 股份代號: 6088 二零二五年中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 管理層討論及分析 | 5 | | 中期財務資料審閱報告 | 15 | | 中期簡明綜合收入表 | 17 | | 中期簡明綜合全面收入表 | 18 | | 中期簡明綜合資產負債表 | 19 | | 中期簡明綜合權益變動表 | 21 | | 中期簡明綜合現金流量表 | 23 | | 中期簡明綜合財務資料附註 | 24 | | 其他資料 | 69 | | 釋義 | 78 | 本中期報告之中英文本如有差異，概以英文本為準。 公司資料 本公司之法定名稱 鴻騰六零八八精密科技股份有限公司（於開曼群島以鴻騰精密科技股份有限公司的名稱註冊成立的有限公司，並以鴻騰六零八 八精密科技股份有限公司於香港經營業務） 上市地點及股份代號 香港聯合交易所有限公司 股份代號：6088 董事 執行董事 盧松青 盧伯卿 ...

Financial Performance - The company achieved revenue of RMB 694.2 million for the six months ended June 30, 2025, representing a growth of 5.6% compared to RMB 657.1 million in the same period of 2024[7]. - Gross profit for the same period was RMB 410.3 million, an increase of 3.0% from RMB 398.5 million year-on-year[7]. - Net profit for the first half of 2025 reached RMB 160.6 million, reflecting a 15.3% increase from RMB 139.3 million in the previous year[7]. - The company reported a basic and diluted earnings per share of RMB 0.14, up from RMB 0.12 in the same period last year[7]. - The company's hip and knee implant products generated revenue of approximately RMB 604.2 million in the first half of 2025, representing an increase of 8.8% year-on-year[16]. - The spinal and trauma implant products reported revenue of approximately RMB 50.7 million, a decline of 26.5% year-on-year[19]. - Revenue from hip joint replacement implants was approximately RMB 409.7 million, a 14.0% increase from RMB 359.4 million in 2024, driven by increased surgical demand[41]. - Revenue from knee joint replacement implants decreased slightly by 0.7% to approximately RMB 194.5 million from RMB 195.8 million in 2024[41]. - Revenue from digital orthopedic customized products and services increased by 3.9% to approximately RMB 18.4 million from RMB 17.7 million in 2024[43]. - Domestic sales revenue was approximately RMB 566.0 million, a 6.0% increase from RMB 533.8 million in 2024, while overseas sales revenue was approximately RMB 128.2 million, up 4.0% from RMB 123.3 million[44]. Market Expansion and Strategy - The company successfully implemented the joint procurement policy for orthopedic medical devices across all provinces in China, leading to a 33% increase in surgical contributions from high-level hospitals[8]. - The company expanded its international market presence, hosting six events under the "Silk Road Health International Cooperation Project," covering 51 medical institutions with over 140 participants[9]. - The company plans to adjust its sales team structure and implement a tiered hospital coverage strategy to enhance market share and solidify its leading position in the domestic orthopedic industry[9]. - The company plans to expand its international market presence, focusing on enhancing brand influence and competitiveness[14]. - The group has registered 4 new countries for overseas operations in the first half of 2025, with 15 additional countries in the registration process and 5 new distributors added[22]. Technological Innovation - The company continues to focus on technological innovation, leading the industry with advancements in 3D printing, personalized platforms, and intelligent navigation technologies[9]. - The company launched the K3 knee joint intelligent navigation robot system and became the first in the orthopedic field to commercialize self-developed robotic arm technology[9]. - The company’s K3 intelligent surgical robot received approval from the National Medical Products Administration, enhancing the iCOS digital orthopedic platform[14]. - The group achieved breakthroughs in smart medical imaging and digital orthopedics, developing a deep learning-based multi-modal imaging fusion algorithm[25]. - The group has built a comprehensive solution network for "preoperative planning - intraoperative digital assistance - postoperative monitoring" to ensure surgical accuracy and efficiency[20]. Research and Development - Research and development expenses for the six months ended June 30, 2025, were approximately RMB 66.7 million, an increase of 4.9% from RMB 63.6 million in 2024, reflecting ongoing investment in R&D projects[50]. - The group has entered 7 products into the national innovation approval channel, maintaining a leading position in the orthopedic field in China[24]. Financial Position and Cash Flow - As of June 30, 2025, the group's cash and cash equivalents totaled approximately RMB 3,751 million, up from RMB 1,027.7 million as of December 31, 2024[53]. - The group's net current assets as of June 30, 2025, were approximately RMB 1,845.5 million, an increase of about RMB 263.9 million from RMB 1,581.6 million as of December 31, 2024[54]. - The group generated a net foreign exchange gain of approximately RMB 53 million for the six months ended June 30, 2025, compared to a foreign exchange loss of RMB 9 million in the same period of 2024[55]. - Total capital expenditures for the six months ended June 30, 2025, were approximately RMB 766 million, primarily for factory construction, patent purchases, and production equipment[56]. - The group reported a profit before tax of RMB 186,671,000 for the six months ended June 30, 2025, compared to RMB 162,524,000 for the same period in 2024, reflecting a growth of 14.8%[85]. Shareholder Information and Equity - As of June 30, 2025, Mr. Li Zhijiang holds 505,157,500 shares, representing 45.00% of the company's equity[116]. - The total issued shares of the company as of June 30, 2025, is 1,122,695,778[116]. - The largest shareholder, Himalaya Limited, holds 505,157,500 shares, which is 45.00% of the company's equity[118]. - The company has no treasury shares as of June 30, 2025[121]. Corporate Governance and Compliance - The audit committee reviewed the interim financial report for the six months ending June 30, 2025, and found it to be in accordance with applicable accounting standards[169]. - The company has adopted a standard code of conduct for securities trading, with all directors confirming compliance for the six months ending June 30, 2025[167]. - The board believes that the current structure of having the same individual serve as both chairman and CEO does not impair the balance of power and authority within the board and management[168].

Revenue and Growth - Revenue for the six months ended June 30, 2025, increased by approximately 3.4% to HKD 540.5 million from HKD 522.6 million in the same period last year[7] - Franchise brand revenue grew by approximately 3.1% to HKD 396.4 million, accounting for about 73.4% of total revenue[11] - Self-operated brand revenue increased by approximately 5.4% to HKD 143.4 million, representing 26.5% of total revenue[13] - Total revenue for the six months ended June 30, 2025, was HKD 540,460,000, an increase from HKD 522,610,000 in the same period of 2024, representing a growth of approximately 3.6%[51] - Restaurant operations generated revenue of HKD 539,793,000, up from HKD 520,666,000, reflecting a growth of 3.9%[64] Cost Management - Food and beverage costs decreased by approximately 3.6% to HKD 156.5 million, with the cost percentage of revenue dropping to 29.0% from 31.1%[16] - Employee costs reduced by approximately 0.9% to HKD 192.6 million, with the cost percentage of revenue decreasing to 35.6% from 37.2%[17] - The company’s employee costs slightly decreased to HKD 192,620,000 from HKD 194,463,000, reflecting a reduction of about 1.0%[51] Financial Performance - The loss attributable to equity holders decreased by approximately 97.6% from HKD 26.5 million to HKD 0.6 million, primarily due to active transformation and restructuring measures[19] - The company reported a pre-tax loss of HKD 2,815,000 for the six months ended June 30, 2025, significantly improved from a loss of HKD 32,069,000 in the same period of 2024[51] - The basic and diluted loss per share for the six months ended June 30, 2025, was HKD 0.08, compared to HKD 3.32 in the same period of 2024, showing a significant reduction in losses per share[51] - The company recorded a net loss of HKD 647,000 for the six months ended June 30, 2025, compared to a loss of HKD 26,535,000 for the same period in 2024[54] Assets and Liabilities - The total assets as of June 30, 2025, amounted to HKD 684,201,000, down from HKD 786,006,000 as of December 31, 2024, indicating a decrease of approximately 13.0%[52] - Total liabilities decreased to HKD 451,943,000 as of June 30, 2025, from HKD 553,141,000 as of December 31, 2024[53] - Current liabilities exceeded current assets by HKD 54,498,000 as of June 30, 2025[58] - The company did not incur any external borrowings as of June 30, 2025[58] Cash Flow and Liquidity - Cash and cash equivalents as of June 30, 2025, were approximately HKD 100.3 million, down from HKD 144.8 million as of December 31, 2024[21] - Operating cash flow for the six months ended June 30, 2025, was HKD 50,015,000, compared to HKD 60,011,000 for the same period in 2024[55] - The company plans to maintain sufficient working capital to meet its financial obligations over the next twelve months[58] Governance and Compliance - The company has adopted the corporate governance code as per the listing rules, ensuring compliance in all significant aspects except for the separation of the roles of Chairman and CEO, which are held by the same individual[37] - The board consists of two executive directors and three independent non-executive directors, maintaining a high level of independence[38] - The audit committee, composed of three independent non-executive directors, has reviewed the company's financial reporting procedures and internal controls[42] - The company confirmed compliance with the standard code for securities trading by all directors during the reporting period[39] Store Operations and Strategy - The number of self-operated restaurants increased to 20 from 14 year-on-year, while the total number of restaurants rose to 64 from 58[10] - The group has actively closed underperforming stores while flexibly opening new potential locations, laying a solid foundation for long-term healthy development[33] - The management is focused on optimizing store portfolio and enhancing customer experience to adapt to changing market dynamics[11] Technology and Innovation - The group continues to embrace new technologies, enhancing operational efficiency through the application of artificial intelligence and automation[34] Dividends - The board decided not to declare an interim dividend for the period, consistent with the previous year[35] - The company did not recommend an interim dividend for the six months ended June 30, 2025, compared to no interim dividend declared for the same period in 2024[82] Impairment and Depreciation - The company identified impairment indicators for several restaurant locations, leading to recorded losses and estimated recoverable amounts for property, plant, and equipment[89] - Depreciation of right-of-use assets for the six months ended June 30, 2025, was HKD 57,353,000, slightly lower than HKD 59,211,000 in 2024[74] - The carrying amount of right-of-use assets for restaurants decreased to HKD 244,881,000 as of June 30, 2025, down from HKD 288,820,000 at the end of 2024, reflecting asset depreciation[84]

Financial Performance - For the six months ended June 30, 2025, the Group's revenue was approximately RMB262,889,000, a decrease of 9.9% compared to RMB291,829,000 in the prior period[14]. - The Group's gross profit for the period was approximately RMB126,076,000, representing a decrease of 9.7% from RMB139,662,000 in the prior period[14]. - The net profit for the period was approximately RMB15,334,000, a decrease of 25.3% compared to RMB20,530,000 in the prior period, primarily due to increased selling and distribution expenses[15]. - Basic and diluted earnings per share were RMB1.93 cents, down from RMB2.85 cents in the prior period[16]. - Total comprehensive income for the period attributable to owners was RMB14,342,000, down 29.5% from RMB20,334,000 in 2024[113]. - Profit for the period was RMB15,334,000, representing a decline of 25.5% from RMB20,530,000 in 2024[113]. - Profit before tax for the six months ended June 30, 2025, was RMB17,490,000, down from RMB23,219,000 in the same period of 2024, representing a decline of 24.0%[136][138]. - The Group's profit before tax for the six months ended June 30, 2025, was RMB17,490,000, down from RMB23,219,000 in the same period of 2024, representing a decline of 24.0%[136][138]. Segment Performance - Revenue from the Faux Leather Chemicals Business decreased by 6.6% to approximately RMB113,104,000, while gross profit for this segment was approximately RMB26,137,000[18]. - The segment revenue from the Chinese Liquor Business was approximately RMB149,785,000, down from RMB170,795,000 in the prior period, with a gross profit of approximately RMB99,940,000[26]. - Segment profit from the Chinese Liquor Business was approximately RMB11,350,000, down from RMB19,817,000 in the prior period[26]. - The segment profit for the Faux leather chemicals was RMB4,951,000, while the Chinese Liquor products segment reported a profit of RMB11,350,000[136]. Expenses and Costs - Selling and distribution expenses for the period were approximately RMB7,942,000, accounting for 7.0% of segment revenue, up from 5.4% in the prior period[23]. - The Group's finance costs increased to RMB960,000 from RMB519,000, representing an increase of 84.9%[155]. - Research and development expenses for the period were RMB3,914,000, slightly down from RMB4,142,000 in 2024[157]. - The Group received government grants totaling RMB1,210,000, down from RMB1,782,000 in 2024, indicating a decrease of 32%[150]. Assets and Liabilities - The current assets of the Group as of June 30, 2025, were approximately RMB652,560,000, up from RMB557,411,000 as of December 31, 2024[39]. - The current liabilities of the Group as of June 30, 2025, were approximately RMB213,407,000, compared to RMB155,653,000 as of December 31, 2024[39]. - The current ratio decreased from approximately 3.58 times as of December 31, 2024, to approximately 3.06 times as of June 30, 2025[39]. - Total segment assets increased to RMB794,306,000 as of June 30, 2025, compared to RMB761,510,000 as of December 31, 2024, reflecting a growth of 4.3%[139]. - The liabilities of the Faux leather chemicals business rose to RMB200,330,000 as of June 30, 2025, from RMB141,054,000 as of December 31, 2024, indicating a significant increase of 42.0%[139]. Cash Flow - Net cash used in operating activities for the six months ended June 30, 2025, was RMB23,227,000, compared to a net cash generated of RMB8,390,000 in 2024[121]. - Net cash used in investing activities was RMB2,285,000, a significant decrease from RMB40,777,000 in the previous year[121]. - The company generated net cash from financing activities amounting to RMB48,132,000, an increase from RMB27,484,000 in the prior year[121]. - Cash and cash equivalents at the end of the period increased to RMB77,819,000 from RMB43,766,000 at the end of June 2024[121]. Shareholder Information - As of June 30, 2025, Mr. Chen Hua held 6,000,800 shares (0.83% of total shareholding) and Mr. Huang Zhenming held 4,000,000 shares (0.56% of total shareholding)[90][92]. - As of June 30, 2025, Sunlight Global Investment Limited and Lilian Global Investment Limited held approximately 0.50% and 0.33% of the total issued share capital of the Company, respectively[93]. - Ms. Zheng Xiuyue holds a long position of 52,000,000 shares, representing approximately 7.22% of the Company's shareholding[99]. - No other persons, apart from Directors and chief executives, had interests or short positions in the shares or underlying shares of the Company as of June 30, 2025[100]. Corporate Governance - The company has adopted the Corporate Governance Code and is committed to transparency and accountability to shareholders[79]. - The company has complied with the Corporate Governance Code since the listing date, with exceptions related to the absence of a Chairman since May 25, 2022[80]. - The Audit Committee, comprising independent non-executive Directors, reviewed the interim financial report and discussed internal control and financial reporting matters[105]. - All directors have complied with the Model Code for Securities Transactions during the reporting period[83]. Strategic Developments - The Group entered into a strategic cooperation agreement with Shanghai Jiuyue in August 2025 to expand the sales of alcoholic beverages and food products[36]. - The Group continues to explore sales channels for its Chinese baijiu products through advertising and hosting tasting events[26]. - The Group's management continues to focus on strategic expansions and partnerships to enhance market presence and operational efficiency[187].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 SHENWAN HONGYUAN (H.K.) LIMITED 申 萬 宏 源 （ 香 港 ） 有 限 公 司 1 茲提述本公司於二零二五年四月三十日刊發的截至二零二四年十二月三十一日止年度之年報（「二零 二四年年報」）。除文義另有所指外，本公告所用詞彙與二零二四年年報所界定者具有相同涵義。 持續關連交易 除二零二四年年報中「關連交易及持續關連交易」一段下的披露外，本公司謹此根據上市規則第 14A 章第 14A.71 條的規定，於二零二四年年報中提供以下進一步資料： (a) 二零二二年申萬宏源集團備忘錄 於二零二二年四月二十日，本公司與申萬宏源集團公司訂立二零二二年申萬宏源集團備忘錄，內容有 關自二零二二年六月一日至二零二五年五月三十一日期間申萬宏源集團與本集團之間可能出現的以 下交易: （於香港註冊成立之有限公司） （股份代號：218） 申萬宏源集團向本集團提供以下服務： 二零二四年年報之補充公告 ...

CONTENTS 目錄 In the first half of 2025, the Group continued to be committed to the development of the water resources industry and the beer industry in Tibet, striving to enhance the user experience and optimize channel expansion, so as to enable Tibet's distinctive and premium products to reach more consumers and potential consumers. | FINANCIAL HIGHLIGHTS | 2 | | --- | --- | | 財務摘要 | | | MANAGEMENT DISCUSSION AND ANALYSIS | 3 | | 管理層討論及分析 | | | CORPORATE GOVERNANCE PRACTICES | 13 | | 公司管治常規 | | | FINANCIAL ...

大唐西市絲路投資控股有限公司 DTXS SILK ROAD INVESTMENT HOLDINGS COMPANY LIMITED (於百慕達註冊成立之有限公司) (股份代號: 620) (Incorporated in Bermuda with limited liability) (Stock Code: 620) 大唐西市絲路投資控股有限公司 DTXS SILK ROAD INVESTMENT HOLDINGS COMPANY LIMITED DTXS SIL K R OAD INVEST MENT HOL DINGS C O MPANY LI MITE D 大 唐 西 市 絲 路 投 資 控 股 有 限 公 司 Interim Report 2025 中 期 報 告 目錄 | 公司資料 | 2 | | --- | --- | | 管理層討論及分析 | 3 | | 其他資料 | 7 | | 簡明綜合損益及其他全面收益表 | 14 | | 簡明綜合財務狀況表 | 16 | | 簡明綜合權益變動表 | 18 | | 簡明綜合現金流量表 | 19 | | 簡明中期財務資料附註 | 20 | 公司資料 董事會 ...

1 擎華控股集團有限公司 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM之定位，乃為較於聯交所上市之其他公司帶有更高投資風險之中小型公司提供一個上 市之市場。有意投資之人士應了解投資於該等公司之潛在風險，並應經過審慎周詳之考慮 後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受 較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容產生或 因倚賴該等內容引致之任何損失承擔任何責任。 本報告乃遵照香港聯合交易所有限公司GEM證券上市規則之規定提供有關擎華控股集團有 限公司之資料。擎華控股集團有限公司各董事願就本報告共同及個別承擔全部責任，並經作 出一切合理查詢後確認，就彼等所深知及確信，本報告所載之資料在各重大方面均屬準確及 完整，且無誤導或欺詐成份；及本報告並無遺漏其他事實致使本報告所載任何陳述產生誤 導。 二零二五年中期報告 2 公司資料 執行董事 唐才智先生 （主席） 鍾楚霖先 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of HK$500 million for the interim period, representing a 25% year-over-year growth[1]. - For the six months ended June 30, 2025, the company's revenue increased by 1.3% to RMB 209.2 million from RMB 206.4 million for the same period in 2024[35]. - The total comprehensive loss for the period was RMB 92.6 million, a decrease from RMB 114.1 million in the same period of 2024[136]. - Adjusted total comprehensive loss for the period was RMB 72.151 million for the six months ended June 30, 2025, compared to RMB 97.659 million for the same period in 2024[51]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[1]. - Gross profit increased by 2.1% to RMB 192.9 million from RMB 188.9 million for the same period in 2024, with a gross profit margin of 92.2% compared to 91.5% in 2024[37]. User Growth and Market Expansion - User data showed a 30% increase in active users, reaching 1.2 million by the end of the reporting period[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[1]. - The company is focusing on accelerating product development and commercialization processes to enhance operational efficiency and bring forward novel medicines[198]. - The company aims to strategically collaborate with partners to expand into emerging markets for the development and commercialization of 恩維達®[200]. Research and Development - Research and development efforts focused on the new PD-L1 inhibitor, ENWEIDA, which is expected to enter clinical trials in Q3 2025[1]. - The company is involved in the research and development of PD-1 and PD-L1 related therapies, targeting non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC)[9]. - The company has advanced a proprietary 177Lu-labeled PSMA-targeted RDC, which is now in the investigator-initiated trial (IIT) stage[29]. - The ongoing development of Envafolimab includes multiple clinical trials demonstrating its efficacy and safety across various cancer types[26][27]. - The company has established a comprehensive nucleic acid drug development system, including drug design, preparation, and preclinical research, with a focus on tumor neoantigen vaccines and the development of the 3D-PreciseAg antigen prediction system[115]. Product Development and Commercialization - The company has commercialized Envafolimab, which is now sold in over 3,000 hospitals and 760+ pharmacies across 30 provinces in China[133]. - Envafolimab achieved sales revenue of RMB 209.2 million in China for the first half of 2025, contributing to a total sales of approximately RMB 1.9 billion[58]. - The company is developing a new mRNA therapeutic cancer vaccine, 3D124, which targets multiple tumor-specific antigens and has shown strong anti-tumor effects in pre-clinical studies[95]. - The production capacity expansion for Envafolimab Injection received official approval from the National Medical Products Administration (NMPA) in the first half of 2025, enhancing manufacturing capabilities to meet growing market demand[125]. Strategic Partnerships and Acquisitions - A strategic acquisition of a local biotech firm was announced, which is expected to enhance the company's product pipeline and capabilities[1]. - The company has initiated a partnership with a leading pharmaceutical company to co-develop new therapies, aiming for a launch by 2026[1]. - The company has established a licensing agreement with Glenmark and is actively pursuing overseas licensing opportunities for Envafolimab in additional countries and regions[62]. Financial Position and Cash Flow - Cash and bank balances as of June 30, 2025, were RMB 660.5 million, down from RMB 864.3 million as of December 31, 2024[34]. - The net cash used in operating activities for the six months ended June 30, 2025, was RMB 205.8 million, compared to RMB 179.7 million for the same period in 2024[170]. - The Group's total revenue increased by approximately 1.3% compared to the corresponding period in 2024, driven by improved market conditions and strong sales execution[58]. - Total current assets decreased by RMB 185.2 million to RMB 802.6 million as of June 30, 2025, from RMB 987.8 million as of December 31, 2024[165][167]. Corporate Governance and Structure - The company has undergone changes in its board of directors, with new appointments and resignations effective June 30, 2025[12]. - The principal bank for the company is Bank of Communications, indicating a stable banking relationship for financial operations[15]. - The company is registered in the Cayman Islands, with its corporate headquarters located in Qingdao, Shandong, PRC[15]. Employee and Operational Insights - The Group had 183 full-time employees as of June 30, 2025, with total employee benefits expenses of approximately RMB 63.4 million for the six months ended June 30, 2025[192]. - Employee recruitment is based on various factors, including work experience and educational background, with ongoing training programs provided to enhance skills and knowledge[197]. - The company is building differentiated commercial capabilities in mainland China and plans to expand these capabilities in the global market[199].

Financial Performance - For the six months ended June 30, 2025, revenue increased to RMB 382.26 million, up 37.5% from RMB 277.84 million in the same period of 2024[19]. - Gross profit for the same period was RMB 149.54 million, representing a 30.3% increase compared to RMB 114.77 million in 2024[19]. - Profit for the period reached RMB 10.26 million, a significant increase of 201.5% from RMB 3.40 million in the previous year[19]. - Earnings per share attributable to ordinary equity holders rose to RMB 3.16 cents, compared to RMB 1.07 cents in 2024, marking a 195.3% increase[19]. - Revenue increased by 37.6% from RMB 277.8 million for the six months ended June 30, 2024, to RMB 382.3 million for the six months ended June 30, 2025[55]. - Revenue from online reading platform services rose by 31.3% from RMB 105.8 million to RMB 139.0 million during the same period, driven by increased online reading advertising[56]. - Revenue from digital marketing services surged by 47.0% from RMB 156.6 million to RMB 230.3 million, attributed to higher advertising demand[57]. - Revenue from online games publishing services grew by 26.3% from RMB 5.3 million to RMB 6.7 million, due to enhanced marketing efforts for an overseas game[58]. - Revenue from other digital content services decreased by 37.8% from RMB 10.1 million to RMB 6.3 million, primarily due to a decline in music digital content revenue[61]. - Cost of sales increased by 42.7% from RMB 163.1 million to RMB 232.7 million, mainly due to rising costs in digital marketing services[62]. - Gross profit margin improved to 39.1% for the six months ended June 30, 2025, compared to 41.3% for the same period in 2024[76]. - Selling and distribution expenses rose by 53.9% to RMB 105.9 million for the six months ended June 30, 2025, accounting for 27.7% of total revenue[78]. - Administrative expenses decreased by 63.8% to RMB 8.4 million for the six months ended June 30, 2025, representing 2.2% of total revenue[79]. - Research and development expenses increased by 26.9% to RMB 22.3 million for the six months ended June 30, 2025, accounting for 5.8% of total revenue[80]. - Profit before tax for the six months ended June 30, 2025, was RMB 11.6 million, up from RMB 5.2 million in 2024[87]. - Net profit for the period increased to RMB 10.3 million for the six months ended June 30, 2025, compared to RMB 3.4 million for the same period in 2024, with a net profit margin of 2.7%[89]. Market and Industry Insights - The global generative AI in content creation market size was USD 14.81 billion in 2024, projected to grow at a CAGR of 32%, reaching USD 134.23 billion by 2032[21]. - The global generative AI content creation market is projected to reach USD 14.81 billion in 2024, with a compound annual growth rate (CAGR) of 32% expected until 2032[23]. - The global in-app purchase revenue from short drama applications reached nearly USD 700 million in Q1 2025, marking a nearly fourfold increase compared to the same period in 2024[30]. Research and Development - R&D expenses for AI-generated content and intelligent recommendation technology amounted to RMB 22.3 million in the first half of 2025[21]. - The company plans to strengthen its core advantages in AI-based recommendation technology and improve recommendation accuracy through algorithm upgrades in the second half of the year[39][42]. - The company will leverage the latest big model technology to build a multi-dimensional content understanding system, enhancing the accuracy and efficiency of its AI engine[40][43]. - The company aims to promote the commercial application of AI technology across various fields, including digital marketing and content generation, to improve marketing conversion efficiency[44][45]. - The company has invested in a series of R&D projects focused on improving the Easou Recommendation Engine, with a total of HK$6.1 million allocated, of which HK$2.9 million has been utilized[180]. Strategic Initiatives - The Group's proprietary Easou Recommendation Engine is continuously upgraded and applied across various business scenarios, enhancing its competitive advantage in the AI sector[6]. - The Group is actively exploring the integration of AI-based recommendation technology with blockchain technology in the RWA sector[7]. - Easou Technology signed a 10-year framework cooperation agreement with a Hong Kong technology company to jointly develop RWA products and other digital asset projects[33]. - The company has established a joint venture with Acceleronet HPC Limited and plans to complete a strategic investment in Lightnet Pte. Ltd. to advance its RWA and Web3.0 initiatives[51][52]. - The strategic partnerships will enable the company to leverage resource advantages and promote the construction of an on-chain rights confirmation and value conversion system for digital assets[52]. User Engagement and Growth - As of June 30, 2025, the cumulative registered users of Easou products reached 47 million, with an average monthly active user count of 25 million[26]. - In the first half of 2025, Easou Technology achieved revenue of RMB 230.3 million in digital marketing services, representing a year-on-year increase of 47.0%[25]. - Easou Technology is actively developing localized and customized short dramas based on overseas user preferences to enhance its globalization strategy[30]. - The company will focus on short drama content as a core entry point for global market expansion, targeting mature markets in Europe and America initially[46][49]. Financial Position and Assets - Total assets increased by 17.2% to RMB 798.2 million as of June 30, 2025, while total liabilities decreased by 27.2% to RMB 171.1 million[95]. - Net current assets rose by 55.6% to RMB 534.5 million as of June 30, 2025, driven by an increase in current assets and a decrease in current liabilities[96]. - Cash and cash equivalents rose by 60.6% from RMB 160.8 million as of December 31, 2024, to RMB 258.4 million as of June 30, 2025, primarily due to proceeds from share placement[122]. - Interest-bearing bank and other borrowings decreased by 31.5% from RMB 193.1 million as of December 31, 2024, to RMB 132.2 million as of June 30, 2025, mainly due to partial repayment of bank borrowings[123]. - The gearing ratio improved to 21.1% as of June 30, 2025, down from 43.3% as of December 31, 2024[124]. Corporate Governance and Shareholder Information - The Company adopted a Share Option Scheme for a period of 10 years starting from the Listing Date, aimed at attracting and retaining quality personnel and aligning their interests with shareholders[130][134]. - The roles of the chairman and CEO are both performed by Mr. Wang, which the Board believes enhances responsiveness and effectiveness in business strategy formulation[155]. - The company will continue to review and monitor its corporate governance practices to ensure compliance with the Corporate Governance Code[156]. - As of June 30, 2025, Mr. Wang holds 106,855,884 shares, representing approximately 27.66% of the company's issued share capital[192]. - The total number of ordinary shares issued by the company as of June 30, 2025, is 386,267,244[193]. - The company does not recommend the payment of any interim dividend for the six months ended June 30, 2025[161].